# Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)

> **NCT03602820** · — · ACTIVE_NOT_RECRUITING · sponsor: **Spark Therapeutics, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Inherited Retinal Dystrophy Due to RPE65 Mutations

## Interventions

- **BIOLOGICAL:** AAV2-hRPE65v2

## Key facts

- **NCT ID:** NCT03602820
- **Lead sponsor:** Spark Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-06
- **Primary completion:** 2030-01
- **Final completion:** 2030-01
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03602820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03602820, "Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03602820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*